Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer
NCT02849327 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2019-09-12
Summary
The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to recurrent pharyngeal cancer.
Conditions
- Recurrent Pharyngeal Cancer
Interventions
- DEVICE
-
Cryosurgery
Percutaneous ablation under CT or ultrasound guidance
- BIOLOGICAL
-
NK immunotherapy
Each treatment: 8\~10 billion cells in all, transfuion in 3 times, i.v.
Sponsors & Collaborators
-
Shenzhen Hank Bioengineering Institute
collaborator OTHER -
Fuda Cancer Hospital, Guangzhou
lead OTHER
Principal Investigators
-
Jibing Chen, MD, PhD · Fuda Cancer Hospital, Guangzhou
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-07-01
- Primary Completion
- 2017-07-01
- Completion
- 2019-07-01
Countries
- China
Study Locations
More Related Trials
-
Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer
NCT02845856 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma
NCT05011227 ·Status: RECRUITING ·Phase: PHASE2
-
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
NCT06802835 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
NCT06533267 ·Status: RECRUITING ·Phase: NA
-
TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma
NCT06912711 ·Status: RECRUITING ·Phase: PHASE2
-
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
NCT03930498 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma
NCT04223024 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer
NCT02843126 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma
NCT06688760 ·Status: RECRUITING ·Phase: NA
-
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
NCT06228079 ·Status: RECRUITING ·Phase: PHASE3
-
Retrospective Investigation of the Impacts of Prognosis for Nasopharyngeal Carcinoma Patients
NCT02604472 ·Status: COMPLETED
-
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
NCT02857920 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07064902 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma
NCT01616849 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma
NCT00817258 ·Status: UNKNOWN ·Phase: PHASE2
-
Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy
NCT04508816 ·Status: COMPLETED ·Phase: PHASE2
-
Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma
NCT05385926 ·Status: RECRUITING ·Phase: PHASE2
-
Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.
NCT06529562 ·Status: RECRUITING ·Phase: NA
-
Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma
NCT02871518 ·Status: UNKNOWN ·Phase: PHASE2
-
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
NCT03666221 ·Status: UNKNOWN ·Phase: PHASE2
-
MK-2206 in Recurrent Nasopharyngeal Carcinoma
NCT01370070 ·Status: COMPLETED ·Phase: PHASE2
-
Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy
NCT02289807 ·Status: WITHDRAWN ·Phase: NA
-
A Study of Nasopharyngeal Carcinoma From Guangdong
NCT03003182 ·Status: UNKNOWN
-
GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma
NCT03723343 ·Status: UNKNOWN
-
Preclinical Research for Personalized TCR-T Therapy for Head and Neck Cancer
NCT05697926 ·Status: RECRUITING